Clusterin Facilitates COMMD1 and I-κB Degradation to Enhance NF-κB Activity in Prostate Cancer Cells
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Secretory clusterin (sCLU) is a stress-activated, cytoprotective chaperone that confers broad-spectrum cancer treatment resistance, and its targeted inhibitor (OGX-011) is currently in phase II trials for prostate, lung, and breast cancer. However, the molecular mechanisms by which sCLU inhibits treatment-induced apoptosis in prostate cancer remain incompletely defined. We report that sCLU increases NF-κB nuclear translocation and transcriptional activity by serving as a ubiquitin-binding protein that enhances COMMD1 and I-κB proteasomal degradation by interacting with members of the SCF-βTrCP E3 ligase family. Knockdown of sCLU in prostate cancer cells stabilizes COMMD1 and I-κB, thereby sequestrating NF-κB in the cytoplasm and decreasing NF-κB transcriptional activity. Comparative microarray profiling of sCLU-overexpressing and sCLU-knockdown prostate cancer cells confirmed that the expression of many NF-κB–regulated genes positively correlates with sCLU levels. We propose that elevated levels of sCLU promote prostate cancer cell survival by facilitating degradation of COMMD1 and I-κB, thereby activating the canonical NF-κB pathway. Mol Cancer Res; 8(1); 119–30
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aggresomes: A Cellular Response to Misfolded Proteins
Johnston, J. A., Ward, C. L., & Kopito, R. R. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.143.7.1883 · Cited by 2,148 · cited 1×
“org ubiquitinated protein inclusions forming specifically at the centrosome (19).”
BackgroundClusterin inhibits apoptosis by interacting with activated Bax
Zhang, H., Kim, J. K., Edwards, C. A., Xu, Z., Taichman, R., & Wang, C.-Y. (2005) · Nature Cell Biology · doi:10.1038/ncb1291 · Cited by 453 · cited 3×
“Proposed mechanisms for its antiapoptotic activity include decreased caspase-3 activation (27) and inhibition of activated Bax (2).”
BackgroundJin, R. J., Lho, Y., Connelly, L., Wang, Y., Yu, X., Saint Jean, L., Case, T. C., Ellwood-Yen, K., Sawyers, C. L., Bhowmick, N. A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0107 · Cited by 182 · cited 1×
“NF-κB is activated in cancer cells by chemotherapy and radiation therapy and is associated with acquired anticancer treatment resistance, including androgen-independent prostate cancer (31-33).”
BackgroundCharacterization and functional consequences of underexpression of clusterin in rheumatoid arthritis
Devauchelle, V., Essabbani, A., De Pinieux, G., Germain, S., Tourneur, L., Mistou, S., Margottin-Goguet, F., Anract, P., Migaud, H., Le Nen, D., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.9.6471 · Cited by 78
Metadata
- Authors
- Zoubeidi, A., Ettinger, S., Beraldi, E., Hadaschik, B., Zardan, A., Klomp, L. W. J., Nelson, C. C., Rennie, P. S., & Gleave, M. E.
- Venue
- Molecular Cancer Research
- Published
- 2010-01-17
- Volume
- 8
- Issue
- 1
- Pages
- 119-130
- ISSN
- 1541-7786 (ISSN-L)
- 1557-3125
- OpenAlex
- W2171286940
- Cited by
- 128
- References
- 4
- FWCI
- 6.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clusterin Facilitates COMMD1 and I-κB Degradation to Enhance NF-κB Activity in Prostate Cancer Cells. https://app.cochat.ai/papers/10.1158/1541-7786.mcr-09-0277
- The paper
- Zoubeidi, A., Ettinger, S., Beraldi, E., Hadaschik, B., Zardan, A., Klomp, L. W. J., Nelson, C. C., Rennie, P. S., & Gleave, M. E. (2010). Clusterin Facilitates COMMD1 and I-κB Degradation to Enhance NF-κB Activity in Prostate Cancer Cells. Molecular Cancer Research. https://doi.org/10.1158/1541-7786.mcr-09-0277
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.